Qise Lian Biotech Secures Series A Funding Led by BVCF to Advance Personalized iPSC-Based Cell Therapies

VCBeat has learned at the earliest opportunity,Qise Lian (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Qise Lian Biotech”)Announced the completion ofBioVeda Capital (BVCF)Exclusive Lead Investment: The funds from this round will be primarily used to accelerate the company’s platform construction and product development. This investment not only demonstrates BioVeda’s confidence in induced pluripotent stem cell (iPSC) therapies but also marks its continued expansion in the biopharmaceutical sector.

Qise Lian Biotech specializes in personalized cell therapy and anti-aging, leveraging next-generation induced pluripotent stem cell (iPSC) technology to develop innovative products and services for autologous cell therapy, regenerative medicine, and health management. By establishing a standardized, large-scale, high-quality cell resource platform, the company provides robust technical support for diverse application scenarios, driving innovation in cell therapy and anti-aging technologies. The team, composed of senior scientists and industry experts, is committed to advancing medical transformation through technological innovation, delivering precise, safe, and accessible solutions to a broader population.

As global population aging intensifies, market demand for cell therapy, regenerative medicine, anti-aging interventions, and health management continues to rise. Induced pluripotent stem cell (iPSC) technology, serving as a critical technological cornerstone in these fields, is garnering increasing attention. iPSC technology enables the reprogramming of an individual’s somatic cells into induced pluripotent stem cells, which can then be directionally differentiated into specific functional cell types or even organs for tissue repair, organ regeneration, and the treatment of various diseases. This highly personalized therapeutic strategy holds promise for delivering more precise and effective treatments for major conditions such as heart failure, severe diabetes, and Parkinson’s disease, while also providing a viable pathway for the construction and transplantation of artificial organs, thereby expanding the clinical boundaries of regenerative medicine.

Regarding securing this round of financing,Dr. Wang Huibing, Founder of Qise Lian BiotechnologyIt indicates that the field of induced pluripotent stem cells (iPSCs) stands at an inflection point, transitioning from scientific exploration to clinical application. Driven by the dual engines of scientific breakthroughs and industrial maturation, this frontier technology is accelerating its journey out of the laboratory and into real-world medical practice. With the iteration of core technologies, the refinement of ethical and regulatory frameworks, and the gradual maturation of upstream and downstream industries, iPSC technology has established a foundation for large-scale implementation. It is increasingly empowering regenerative medicine and personalized therapy, unleashing its immense potential in disease treatment and health management.

Dr. Yang Zhi, Partner at BiovedaBioVeda stated: “As an investment firm with significant influence in the biomedical sector, BioVeda has consistently focused on cutting-edge technological advancements. This investment underscores our strong confidence in the fields of iPSC-based therapies and anti-aging. In recent years, iPSC technology has made remarkable progress in cell therapy, with its potential widely recognized in anti-aging, regenerative medicine, and the treatment of various chronic diseases. BioVeda’s investment will provide robust financial support to this anti-aging company, accelerating its R&D efforts and product development.”